Synthesis, metabolic stability and chemotactic activity of peptide T and its analogues

Publisher Website
Google Scholar
Abstract
Acquired immunodeficiency syndrome (AIDS) is initiated by the attachment of the human immunodeficiency virus (HIV) to a surface glycoprotein CD4 present on T4 helper/inducer lymphocytes, monocytes/macrophages and other cells. A simple octapeptide (H-Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr-OH, peptide T) seems to inhibit HIV infectivity and to activate human monocyte chemotaxis. In order to study in vitro metabolic stability and structure-activity relationships, peptide T and a number of analogues were prepared and tested on human monocytes by chemotactic assay. Peptide T and the shorter fragments T(3-8)-OH and T(4–8)-OH displayed potent bioactivity (maximal chemotactic activity in the range 10-11-10-10M). The C-terminal heptapeptide showed a reduction of potency, while further truncations at N-terminus of T(4–8)-OH abolished the biological action. In the octapeptide series, whereas the α-amino butyric acid (Abu) substitution for Thr4 was well tolerated, the same “slight” structural change at Thr5 or Thr8 was very detrimental. Finally, [d-Asn6]T(1-8)-OH analogue has low chemotactic activity. All these results indicate that i) the C-terminal pentapeptide is the minimum sequence required for bioactivity, ii) residues 5 to 8 appear to play a crucial biological role, iii) peptide T chemotaxis is mediated, at least in part, through the polar properties of Thr side chains at the critical positions 5 and 8, while the Thr4 does not interfere with biological characteristics of peptides. With regard to the enzymic degradation, the in vitro experiments showed the susceptibility of peptide T to rapid metabolism by human or rat plasma (T1/2 = 5.2 min), rat brain (T1/2 = 2.1 min) and kidney (T1/2 = 0.4 min) enzymes. The main metabolic product appears to be the C-terminal heptapeptide, which retains, in turn, a low enzymatic stability.